General form of registration statement for all companies including face-amount certificate companies

Consolidated Statements of Cash Flows

v3.5.0.1
Consolidated Statements of Cash Flows - USD ($)
 6 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Sep. 30, 2015
Sep. 30, 2014
Cash flows from operating activities:        
Net Loss $ (2,409,711) $ (454,821) $ (2,947,526) $ (8,142,823)
Adjustments to reconcile net loss to cash used in operating activities:        
Depreciation Expense     0 322
Stock-based compensation 358,330 609,272 1,047,685 1,101,286
Noncash interest expense on notes payable 210,569 78,320 377,805 111,059
Issuance of restricted stock for services 52,500 8,625 166,157 94,875
Gain on exercise of warrants and conversion of debt (142,964) (224,000) (386,612) 0
Loss on warrant derivative modification 0 1,924,186 1,032,113 0
Decrease to fair value of derivative (192,128) (3,849,448) (3,536,294) (4,121,693)
Fair value of derivative liabilities in excess of proceeds     0 7,541,693
Issuance of common stock for services     0 92,500
(Increase) decrease in:        
Prepaid expenses and other current assets (47,200) 11,029 551 (13,779)
Increase (decrease) in:        
Accounts payable (96,146) 28,267 55,929 (138,937)
Accrued expenses and other liabilities (64,101) 58,650 (49,194) 126,995
Net cash used in operating activities (2,330,851) (1,809,920) (4,239,386) (3,348,502)
Cash flows from financing activities:        
Proceeds from exercise of warrants 40,000 800,000 3,600,000 0
Proceeds from issuance of common stock and warrants     3,015,966 2,624,703
Proceeds from issuance of convertible notes 0 750,000 750,000 0
Proceeds from issuance of notes payable     0 1,000,000
Net cash provided by financing activities 40,000 1,550,000 7,365,966 3,624,703
Net increase in cash (2,290,851) (259,920) 3,126,580 276,201
Cash, beginning of period 3,960,100 833,520 833,520 557,319
Cash and cash equivalents, end of period 1,669,249 573,600 3,960,100 833,520
Non-cash financing activities        
Issuance of Inducement shares     135,352 0
Conversion of 8% convertible notes and accrued interest to common stock $ 536,278 $ 0 151,173 0
Reclassification of Series A and C Warrants from derivative liabilities to equity     3,263,753 0
Conversion feature embedded in convertible note     $ 354,988 $ 0